Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PTO Lobbies Against Damages Award Provision in Patent Reform Bill

Executive Summary

The U.S. Patent and Trademark Office has launched a full court press to get the Senate Judiciary Committee to revise its patent reform bill

You may also be interested in...



Patent Reform Provision Extending Angiomax Patent Would Cost $1 Bil. – CBO

The Medicines Company scored a lobbying victory when a provision was tucked into patent reform legislation that would authorize the Patent and Trademark Office to accept late applications

Patent Reform Provision Extending Angiomax Patent Would Cost $1 Bil. – CBO

The Medicines Company scored a lobbying victory when a provision was tucked into patent reform legislation that would authorize the Patent and Trademark Office to accept late applications

Senators Oppose Patent Reform Provisions; GSK Also Urges Revisions To Bill

As patent reform legislation heads toward the Senate floor, members of the biotech and pharmaceutical industries are imploring legislators to alter key provisions. And a group of Senators is criticizing the bill's formulation for apportioning damage awards in infringement suits

UsernamePublicRestriction

Register

PS049295

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel